Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium
04 déc. 2019 09h00 HE
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that response and clinical benefit data from its Phase 2 study of dectin-1 agonist Imprime PGG in...